Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Operating Expenses (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Operating Expenses for 10 consecutive years, with $53.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 32.64% to $53.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $173.2 million through Dec 2025, up 17.47% year-over-year, with the annual reading at $173.2 million for FY2025, 17.47% up from the prior year.
  • Operating Expenses for Q4 2025 was $53.6 million at Akebia Therapeutics, up from $44.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $88.8 million in Q1 2022, with the low at $35.3 million in Q2 2024.
  • Average Operating Expenses over 5 years is $55.0 million, with a median of $46.8 million recorded in 2023.
  • The sharpest move saw Operating Expenses tumbled 48.89% in 2023, then surged 32.64% in 2025.
  • Over 5 years, Operating Expenses stood at $75.4 million in 2021, then fell by 15.0% to $64.1 million in 2022, then tumbled by 43.58% to $36.2 million in 2023, then rose by 11.84% to $40.4 million in 2024, then soared by 32.64% to $53.6 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $53.6 million, $44.9 million, and $38.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.